Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study
Introduction: Remdesivir has shown broad-spectrum antiviral activity. This drug is approved by the Food and Drug Administration for coronavirus disease 2019 (COVID-19) management. Other than a few case series and case reports, not much information is available on its use in kidney transplant recipie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Indian Journal of Transplantation |
| Subjects: | |
| Online Access: | http://www.ijtonline.in/article.asp?issn=2212-0017;year=2022;volume=16;issue=2;spage=216;epage=219;aulast=Latief |
| _version_ | 1818509429338800128 |
|---|---|
| author | Muzamil Latief Farhat Abbas Mohd Iqbal Zhahid Hassan L Naresh Goud Obeid Shafi |
| author_facet | Muzamil Latief Farhat Abbas Mohd Iqbal Zhahid Hassan L Naresh Goud Obeid Shafi |
| author_sort | Muzamil Latief |
| collection | DOAJ |
| description | Introduction: Remdesivir has shown broad-spectrum antiviral activity. This drug is approved by the Food and Drug Administration for coronavirus disease 2019 (COVID-19) management. Other than a few case series and case reports, not much information is available on its use in kidney transplant recipients (KTRs). Materials and Methods: We describe our experience of seven KTRs with COVID-19. All the patients were hypoxemic. High-resolution computed tomography (CT) chest was done in all the patients. Injection remdesivir 200 mg on day 1 followed by 100 mg daily was given for a maximum of 5 days irrespective of estimated glomerular filtration rate (eGFR). Observations and Results: Mean age of patients was 46.28 ± 10.41 years and one patient was female. Mean CT severity score was 15. In our study, 2 patients who required mechanical ventilation expired. None of our patient had worsening of acute kidney injury (AKI) or new-onset AKI after institution of remdesivir. Discussion: Optimal management for this patient population remains unknown, therefore, treatment of COVID-19 in KTRs varies from center to center. The studies on remdesivir use in KTRs with COVID-19 are not extensive. Our series does indicate safety of remdesivir in KTRs. Conclusion: We observed that remdesivir can be used in KTRs with COVID-19 with hypoxemia irrespective of eGFR. We suggest that large-scale studies should be done to substantiate these findings. |
| first_indexed | 2024-12-10T22:45:20Z |
| format | Article |
| id | doaj.art-b67168a5c817442eafa8d64b7e0519bf |
| institution | Directory Open Access Journal |
| issn | 2212-0017 2212-0025 |
| language | English |
| last_indexed | 2024-12-10T22:45:20Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Transplantation |
| spelling | doaj.art-b67168a5c817442eafa8d64b7e0519bf2022-12-22T01:30:35ZengWolters Kluwer Medknow PublicationsIndian Journal of Transplantation2212-00172212-00252022-01-0116221621910.4103/ijot.ijot_54_21Remdesivir in renal transplant patients with coronavirus disease 2019: An observational studyMuzamil LatiefFarhat AbbasMohd IqbalZhahid HassanL Naresh GoudObeid ShafiIntroduction: Remdesivir has shown broad-spectrum antiviral activity. This drug is approved by the Food and Drug Administration for coronavirus disease 2019 (COVID-19) management. Other than a few case series and case reports, not much information is available on its use in kidney transplant recipients (KTRs). Materials and Methods: We describe our experience of seven KTRs with COVID-19. All the patients were hypoxemic. High-resolution computed tomography (CT) chest was done in all the patients. Injection remdesivir 200 mg on day 1 followed by 100 mg daily was given for a maximum of 5 days irrespective of estimated glomerular filtration rate (eGFR). Observations and Results: Mean age of patients was 46.28 ± 10.41 years and one patient was female. Mean CT severity score was 15. In our study, 2 patients who required mechanical ventilation expired. None of our patient had worsening of acute kidney injury (AKI) or new-onset AKI after institution of remdesivir. Discussion: Optimal management for this patient population remains unknown, therefore, treatment of COVID-19 in KTRs varies from center to center. The studies on remdesivir use in KTRs with COVID-19 are not extensive. Our series does indicate safety of remdesivir in KTRs. Conclusion: We observed that remdesivir can be used in KTRs with COVID-19 with hypoxemia irrespective of eGFR. We suggest that large-scale studies should be done to substantiate these findings.http://www.ijtonline.in/article.asp?issn=2212-0017;year=2022;volume=16;issue=2;spage=216;epage=219;aulast=Latiefcoronavirus disease 2019kidney transplant recipientremdesivir |
| spellingShingle | Muzamil Latief Farhat Abbas Mohd Iqbal Zhahid Hassan L Naresh Goud Obeid Shafi Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study Indian Journal of Transplantation coronavirus disease 2019 kidney transplant recipient remdesivir |
| title | Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study |
| title_full | Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study |
| title_fullStr | Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study |
| title_full_unstemmed | Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study |
| title_short | Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study |
| title_sort | remdesivir in renal transplant patients with coronavirus disease 2019 an observational study |
| topic | coronavirus disease 2019 kidney transplant recipient remdesivir |
| url | http://www.ijtonline.in/article.asp?issn=2212-0017;year=2022;volume=16;issue=2;spage=216;epage=219;aulast=Latief |
| work_keys_str_mv | AT muzamillatief remdesivirinrenaltransplantpatientswithcoronavirusdisease2019anobservationalstudy AT farhatabbas remdesivirinrenaltransplantpatientswithcoronavirusdisease2019anobservationalstudy AT mohdiqbal remdesivirinrenaltransplantpatientswithcoronavirusdisease2019anobservationalstudy AT zhahidhassan remdesivirinrenaltransplantpatientswithcoronavirusdisease2019anobservationalstudy AT lnareshgoud remdesivirinrenaltransplantpatientswithcoronavirusdisease2019anobservationalstudy AT obeidshafi remdesivirinrenaltransplantpatientswithcoronavirusdisease2019anobservationalstudy |